NextCure, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NXTC research report →
Companywww.nextcure.com
NextCure, Inc. , a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors.
- CEO
- Michael S. Richman
- IPO
- 2019
- Employees
- 43
- HQ
- Beltsville, MD, US
Price Chart
Valuation
- Market Cap
- $25.85M
- P/E
- -0.92
- P/S
- 0.00
- P/B
- 1.89
- EV/EBITDA
- -0.27
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -186.96%
- ROIC
- -180.46%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-55,844,000 · -0.34%
- EPS
- $-19.65 · 17.71%
- Op Income
- $-57,616,000
- FCF YoY
- -20.19%
Performance & Tape
- 52W High
- $15.74
- 52W Low
- $4.60
- 50D MA
- $10.74
- 200D MA
- $9.91
- Beta
- 1.43
- Avg Volume
- 49.51K
Get TickerSpark's AI analysis on NXTC
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 30, 26 | Shaw Kevin G. | other | 8,270 |
| Jan 30, 26 | Guha Udayan | other | 14,670 |
| Jan 30, 26 | Kundu Sourav | other | 8,270 |
| Jan 30, 26 | Mayer Timothy | other | 14,670 |
| Jan 30, 26 | Richman Michael | other | 38,190 |
| Jan 30, 26 | Cobourn Steven P. | other | 14,670 |
| Jun 20, 25 | Simcere Zaiming, Inc. | other | 0 |
| Jun 20, 25 | Houston John G | other | 18,700 |
| Jun 20, 25 | Jones Elaine V | other | 18,700 |
| Jun 20, 25 | KABAKOFF DAVID S | other | 28,050 |
Our NXTC Coverage
We haven't published any research on NXTC yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NXTC Report →